Biogen Inc. (NASDAQ:BIIB) may be the Goliath in the $17 billion (and growing) market for multiple sclerosis (MS) treatment, but it’s Novartis’ (NYSE:NVS) Gilenya, not Biogen’s Tecfidera, that’s growing more quickly this year.
Some background
MS is a central nervous system disorder caused when the immune system incorrectly damages the protective myelin sheath surrounding nerve fibers, causing nerves to lose their ability to transmit information quickly and efficiently.
